These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26452759)

  • 1. A case report: retigabine induced oral mucosal dyspigmentation of the hard palate.
    Beacher NG; Brodie MJ; Goodall C
    BMC Oral Health; 2015 Oct; 15(1):122. PubMed ID: 26452759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine.
    Garin Shkolnik T; Feuerman H; Didkovsky E; Kaplan I; Bergman R; Pavlovsky L; Hodak E
    JAMA Dermatol; 2014 Sep; 150(9):984-9. PubMed ID: 25006968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retigabine: blue skin discoloration and retinal pigment abnormalities.
    Prescrire Int; 2013 Nov; 22(143):269. PubMed ID: 24427841
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety of retigabine in adults with partial-onset seizures after long-term exposure: focus on unexpected ophthalmological and dermatological events.
    Brickel N; Hewett K; Rayner K; McDonald S; De'Ath J; Daniluk J; Joshi K; Boll MC; Tiamkao S; Vorobyeva O; Cooper J
    Epilepsy Behav; 2020 Jan; 102():106580. PubMed ID: 31731109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal pigmentation of the hard palate in a patient taking imatinib.
    Lyne A; Creedon A; Bailey BM
    BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25883257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the long-term behavioral effects of neonatal exposure to retigabine or phenobarbital in rats.
    Frankel S; Medvedeva N; Gutherz S; Kulick C; Kondratyev A; Forcelli PA
    Epilepsy Behav; 2016 Apr; 57(Pt A):34-40. PubMed ID: 26921596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retigabine: fewer drug interactions.
    Prescrire Int; 2012 Mar; 21(125):61. PubMed ID: 22428181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The possibility of adverse effect of Kv7-channel opener retigabine on memory processes in rats.
    Zwierzyńska E; Krupa-Burtnik A; Pietrzak B
    Epilepsy Behav; 2017 Oct; 75():170-175. PubMed ID: 28866337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability exposure-response relationship of retigabine (ezogabine) immediate-release tablets in patients with partial-onset seizures.
    Tompson DJ; Crean CS; Reeve R; Berry NS
    Clin Ther; 2013 Aug; 35(8):1174-1185.e4. PubMed ID: 23916044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The color of skin: blue diseases of the skin, nails, and mucosa.
    Cohen PR
    Clin Dermatol; 2019; 37(5):468-486. PubMed ID: 31896403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial Combination of Lacosamide with Retigabine in Experimental Animals: An Isobolographic Analysis.
    Luszczki JJ; Zagaja M; Miziak B; Kondrat-Wrobel MW; Zaluska K; Wroblewska-Luczka P; Adamczuk P; Czuczwar SJ; Florek-Luszczki M
    Pharmacology; 2018; 101(1-2):22-28. PubMed ID: 28926841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two cases of oral pigmentation associated with quinidine therapy.
    Birek C; Main JH
    Oral Surg Oral Med Oral Pathol; 1988 Jul; 66(1):59-61. PubMed ID: 3165515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal calcified nodule of the hard palate in an infant: case report and review of the literature.
    Afzal MN; Dancea S; de Nanassy J
    Pediatr Pathol Lab Med; 1997; 17(4):611-5. PubMed ID: 9211554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palate hyperpigmentation caused by prolonged use of the anti-malarial chloroquine.
    de Melo Filho MR; da Silva CA; da Rocha Dourado M; de Oliveira Pires MB; Pêgo SP; de Freitas EM
    Head Neck Pathol; 2012 Mar; 6(1):48-50. PubMed ID: 21877232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solitary mucosal neuroma of the hard palate: a case report.
    Nishihara K; Yoshida H; Onizawa K; Yusa H; Fujiwara M
    Br J Oral Maxillofac Surg; 2004 Oct; 42(5):457-9. PubMed ID: 15336775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minocycline-associated intra-oral soft-tissue pigmentation: clinicopathologic correlations and review.
    LaPorta VN; Nikitakis NG; Sindler AJ; Reynolds MA
    J Clin Periodontol; 2005 Feb; 32(2):119-22. PubMed ID: 15691339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and characterization of an oral mucosal melanoma cell line (MEMO) derived from a longstanding primary oral melanoma.
    Lourenço SV; Bologna SB; Hsieh R; Sangueza M; Fernandes JD; Nico MM
    Am J Dermatopathol; 2013 Apr; 35(2):248-51. PubMed ID: 23249835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of ezogabine (retigabine) in adults with refractory partial-onset seizures: Interim results from two ongoing open-label studies.
    Gil-Nagel A; Brodie MJ; Leroy R; Cyr T; Hall S; Castiglia M; Twomey C; VanLandingham K
    Epilepsy Res; 2012 Nov; 102(1-2):117-21. PubMed ID: 22771137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a single dose of retigabine in cortical excitability parameters: A cross-over, double-blind placebo-controlled TMS study.
    Ossemann M; de Fays K; Bihin B; Vandermeeren Y
    Epilepsy Res; 2016 Oct; 126():78-82. PubMed ID: 27448328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-retigabine: an N-propargyled retigabine with improved brain distribution and enhanced antiepileptic activity.
    Zhou P; Zhang Y; Xu H; Chen F; Chen X; Li X; Pi X; Wang L; Zhan L; Nan F; Gao Z
    Mol Pharmacol; 2015 Jan; 87(1):31-8. PubMed ID: 25319542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.